Sofie Geelissen

• Lead Benelux neurology and psychiatry team (11 FTE) with low turnover, managing neuroscience pre-launch and launch, budget, medical strategy, and planning.
• Simplified processes for KOL engagement plans and launch readiness.
• Enhanced real-world evidence programs including telemonitoring and AI, implemented investigator-initiated studies.
• Directed significant change in medical affairs culture
• Active in local Pharmaceutical Company Association (VIG & Pharma.be).

Led creation of new Patient Value team (7 FTE) in medical affairs during a January 2023 reorganization across all TA (oncology, hematology, rare diseases, immunology, neurosciences, PAH)

• Inspired multiple teams by establishing clear organizational direction.
• Implemented KPIs to assess performance
• Streamlined patient value processes with medical affairs workflows, e.g., insights.
• Developed innovative solutions addressing patient insights and business needs leveraging on in-depth healthcare knowledge.
• Led strategic patient advisory board and BeLux patient inspiration day.
• Member of the European Patient Engagement Leadership team and active in the local Pharmaceutical Company Association (Pharma.be).

• Additional role alongside Medical Affairs Lead
• Led pricing and reimbursement strategy for a psychiatry product, securing successful MEA negotiations and resolving key healthcare issues
• Developed health economic models and led revision dossier for psoriatic arthritis in dermatology/rheumatology
• Create strategy and reimbursement dossier for lung cancer

• Key player in BeLux leadership team, guiding affiliate Medical Affairs team and neonatology commercial locally.
• Shifted medical role from reactive to strategic business co-leader and expanding (3 to 11) FTE with minimal turnover.
• Spearheaded the affiliate reorganization (law Renault) with strategic vision, fostering holistic thinking, and engaging communication.
• Drove patient/market access initiatives, established early access programs, and contributed to MEA negotiations, collaboration with governmental bodies.
• Implemented three pioneering digital solutions to bridge identified gaps
• Directed launch of seven therapeutic indications.
• Managed all aspects of local Phase 4 clinical trials and supported investigator-led research.
• Participated in international taskforces assessing MSL efficiency.
• Engaged in local Pharmaceutical Company Association (Pharma.be).

• Formulated strategy and tactical plans for rare metabolic, ophthalmologic, hematologic, and nephrologic conditions.
• Fostered enduring collaborations with HCP and patient organizations.
• Authored scientific parts of reimbursement dossiers and D60 answers, presented at hearings, and published post-hoc analyses.
• Spearheaded launch strategy for in-licensed allergic rhinitis and asthma products
• Managed pre-launch of two rare disease indications, launch of one indication, and LCM of neonatology indication.
• Initiated local observational trial for Belgian cystinosis patients.

• Formulated and implemented strategic plans for addressing rare metabolic diseases, auto-inflammatory conditions, and autoimmune disorders.
• Managed investigator-initiated trials and global PASS studies.
• Resolved access challenges for patients with rare auto-inflammatory conditions in BeNeLux.
• Developed solid HCP network.
• Developed medical performance indicators with international team collaboration.
• Received the SOBI Care Award for excellence in collaborative value.
• Directed Europe medical strategy for iron chelation since July 2016.

• Managed a global team exceeding 60 FTEs.
• Directed budget planning, CRO monitoring and optimized processes.
• Collaborated closely with VPs in R&D, Medical Affairs, Health Economics, and Commercial sectors.
• Directed Corporate Integrity Agreement (CIA) compliance, developing self-inspections, monitoring plans, and risk management strategies, resulting in zero major findings and significantly reduced minor findings over 2 years.
• Executed significant change management initiatives for processes.

• Oversaw global integrated publication plan for clinical, health economics, medical, and regional/global levels.
• Managed a team of 11 publication managers, both global and regional.
• Led strategic publication platform and relevant workgroups.
• Cultivated strong relationships with HCPs and led the steering committee.
• Honored with ClinOps silver award in 2011.

• Publication Manager HPV Vaccines (02/2008-11/2009) - contractor for GSK
• Medical Writer Manager (GMA) (05/2008-03/2009) - contractor for UCB
• Medical Writer (05/2007-05/2008) - contractor for UCB
• Medical writing domain leader for Business&Decision (01/2008-10/2010)
• Data reviewer and Medical Writer - SGS (Aug 2006-May 2007)
• Clinical Research Data Administrator - contractor for Boston Scientific (May 2006-Aug 2006)